scispace - formally typeset
Search or ask a question

Answers from top 7 papers

More filters
Papers (7)Insight
Trimetazidine exerts its anti-ischemic action by modulating cardiac metabolism without altering the hemodynamic functions, therefore represents an excellent complementary potential to the conventional angina treatment.
Trimetazidine administered a few days before PTCA appears to be a cardioprotective agent for the prevention of myocardial ischaemia.
These results suggest that trimetazidine protects against dephosphorylation of nucleotides and ischemic damage.
Such a protective effect may participate in the antiaggregatory properties of trimetazidine.
The present data suggest that trimetazidine may be an effective adjunct therapy for these patients, but further investigation is needed to confirm these findings.
The membrane effects reported here could participate in the protection of cell metabolism afforded by a long-term treatment with trimetazidine.
The present observations indicate the need of further research to explore the effect of trimetazidine during longer treatment period or with more selected patient population.